Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer

Nature

Volumn 513, Issue 7518, 2014, Pages 436-439

  Suh, Jae Myoung ^a   Jonker, Johan W ^b   Ahmadian, Maryam ^a   Goetz, Regina ^c   Lackey, Denise ^d   Osborn, Olivia ^d   Huang, Zhifeng ^c,g   Liu, Weilin ^b   Yoshihara, Eiji ^a   Van Dijk, Theo H ^b   Havinga, Rick ^b   Fan, Weiwei ^a   Yin, Yun Qiang ^a   Yu, Ruth T ^a   Liddle, Christopher ^e   Atkins, Annette R ^a   Olefsky, Jerrold M ^d   Mohammadi, Moosa ^c   Downes, Michael ^a   Evans, Ronald M ^a,f  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 1; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR 1; MITOGENIC AGENT;

DIABETES; GERM CELL; GLUCOSE; GROWTH RATE; HOMEOSTASIS; PROTEOMICS; SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BINDING AFFINITY; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FATTY LIVER; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; HYPOGLYCEMIA; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; MALE; MITOGENESIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOLYSIS; PANCREAS ISLET BETA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HUMAN; LIPID DIET; LIVER; METABOLISM; MOUSE MUTANT;

MUS;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTOR 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MITOGENS; MUSCLE, SKELETAL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84906826372     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13540     Document Type: Article

References (16)

1. Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nature Rev. Drug Discov. 8, 235-253 (2009).
2. Itoh, N. & Ornitz, D. M. Fibroblast growth factors: frommolecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121-130 (2011).
3. Jonker, J. W. et al. A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391-394 (2012).
4. Sun, K.& Scherer, P. E. The PPARγ-FGF1 axis: an unexpected mediator of adipose tissue homeostasis. Cell Res. 22, 1416-1418 (2012).
5. Lehrke, M. & Lazar, M. A. The many faces of PPARc. Cell 123, 993-999 (2005).
6. Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635 (2005).
7. Dutchak, P. A. et al. Fibroblast growth factor-21 regulates PPARc activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556-567 (2012).
8. Zinn, K. R. et al. Imaging Tc-99m-labeled FGF-1 targeting in rats. Nucl. Med. Biol. 27, 407-414 (2000).
9. Lee, J. & Blaber, M. The interaction between thermodynamic stability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1. J. Mol. Biol. 393, 113-127 (2009).
10. Wu, A. L. et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3, 113ra126 (2011).
11. Li, A. J., Tsuboyama, H., Komi, A., Ikekita, M. & Imamura, T. Strong suppression of feeding by a peptide containing both the nuclear localization sequence of fibroblast growth factor-1 and a cell membrane-permeable sequence. Neurosci. Lett. 255, 41-44 (1998).
12. Suzuki, S. et al. Feeding suppression by fibroblast growth factor-1 is accompanied by selective induction of heat shock protein 27 in hypothalamic astrocytes. Eur. J. Neurosci. 13, 2299-2308 (2001).
13. Sasaki, K. et al. Effects of fibroblast growth factors and related peptides on food intake by rats. Physiol. Behav. 56, 211-218 (1994).
14. Wei, W. et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor c. Proc. Natl Acad. Sci. USA 109, 3143-3148 (2012).
15. Holland, W. L. et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790-797 (2013).
16. Lin, Z. et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779-789 (2013).